Esperion Therapeutics Inc... (ESPR)
NASDAQ: ESPR
· Real-Time Price · USD
2.56
0.13 (5.35%)
At close: Sep 25, 2025, 3:59 PM
2.59
1.17%
After-hours: Sep 25, 2025, 07:33 PM EDT
Esperion Therapeutics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue Revenue | 42.11M | 30.08M | 83.08M | 20.53M | 45.53M | 112.98M | 11.49M | 13.72M | 5.49M | 7.3M | 3.85M | 5.02M | 5.26M | 5.48M | 3.21M | 3.51M | 30.05M | 1.63M | 1.47M | 502K | 211.63M | 982K |
| Collaboration Revenue Revenue Growth | +39.99% | -63.79% | +304.77% | -54.92% | -59.70% | +883.28% | -16.24% | +149.74% | -24.73% | +89.51% | -23.23% | -4.69% | -3.99% | +70.83% | -8.68% | -88.31% | +1745.76% | +10.67% | +193.03% | -99.76% | +21450.61% | n/a |
| Product Revenue | 40.27M | 34.91M | 59.86M | 31.11M | 28.3M | 24.76M | 20.76M | 20.25M | 20.29M | 17.03M | 14.97M | n/a | n/a | n/a | 12.19M | n/a | n/a | n/a | 8.17M | n/a | n/a | 858K |
| Product Revenue Growth | +15.36% | -41.68% | +92.45% | +9.91% | +14.32% | +19.25% | +2.51% | -0.21% | +19.15% | +13.79% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 39.51M | 43M | 36.92M | 39.98M | 44.19M | 41.99M | 45.42M | 33.24M | 33.96M | 29.9M | 24.14M | 24.95M | 29.61M | 30.38M | 38.34M | 39.27M | 46.32M | 61.06M | 61.55M | 48.83M | 47.68M | 41.55M | 21.71M | 18.47M | 13.49M | 12.18M | 11.18M | 9.01M | 6.96M | 5.95M | 5.26M | 5.68M | 5.41M | 5.03M | 4.4M | 4.21M | 4.63M | 5.03M | 5.28M | 5.67M | 5.25M | 4.04M |
| Selling, General, and Administrative Revenue Growth | -8.11% | +16.44% | -7.63% | -9.53% | +5.23% | -7.56% | +36.65% | -2.12% | +13.57% | +23.88% | -3.27% | -15.72% | -2.54% | -20.75% | -2.36% | -15.23% | -24.15% | -0.80% | +26.07% | +2.40% | +14.75% | +91.38% | +17.57% | +36.88% | +10.75% | +9.00% | +24.03% | +29.54% | +16.83% | +13.26% | -7.46% | +4.97% | +7.62% | +14.19% | +4.51% | -9.04% | -7.91% | -4.68% | -6.95% | +7.98% | +30.19% | n/a |
| Research and Development Revenue | 7.24M | 12.56M | 10.98M | 10.4M | 11.46M | 13.4M | 17.74M | 14.88M | 22.1M | 31.38M | 33.03M | 29.14M | 32.43M | 24.32M | 27.62M | 25.33M | 25.07M | 27.95M | 41.96M | 35.28M | 34.99M | 34.7M | 38.23M | 48.28M | 42.79M | 46.31M | 49.47M | 41.55M | 39.52M | 40.94M | 33.44M | 40.06M | 38.25M | 35.86M | 24.88M | 13.5M | 9.7M | 9.79M | 7.96M | 7.25M | 7.21M | 7.39M |
| Research and Development Revenue Growth | -42.36% | +14.39% | +5.58% | -9.28% | -14.49% | -24.46% | +19.19% | -32.64% | -29.58% | -5.00% | +13.35% | -10.14% | +33.36% | -11.94% | +9.02% | +1.02% | -10.30% | -33.39% | +18.94% | +0.85% | +0.82% | -9.24% | -20.81% | +12.84% | -7.60% | -6.40% | +19.07% | +5.13% | -3.46% | +22.43% | -16.52% | +4.73% | +6.66% | +44.13% | +84.33% | +39.18% | -0.95% | +23.06% | +9.78% | +0.53% | -2.45% | n/a |